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Background: Clostridium difficile (CD) has increasingly become recognised as a significant international health
burden, often associated with the healthcare environment. The upsurge in incidence of CD coincided with the
emergence of a hypervirulent strain of CD characterized as 027.
In 2010, 8 cases of CD 027 infections were identified in Italy. Since then, no further reports have been published.
We describe 10 new cases of CD 027 infection occurring in Italy.
Methods: Since December 2010, stool samples of patients with severe diarrhea and clinical suspicion of the
presence of a hypervirulent strain, were tested for CD 027 by the Xpert C. difficile PCR assay (Cepheid, Sunnyvale,
CA). Clinical, epidemiological and laboratory data were collected.
Results: From December 2010 to April 2012, 24 faecal samples from 19 patients who fit the above criteria were
submitted to our laboratory. Samples were collected from 7 different hospitals.
Of these, 17 had a positive PCR for CD and 10 were the epidemic 027 strain (59%). All PCR positive samples had a
positive EIA toxin A/B test. Nine of 10 patients were recently exposed to antimicrobials and were healthcare-
associated, including 4 with a history of long term care facility (LTCF) admission; the remaining case was
community-associated, namely the wife of a patient with hospital-acquired CD 027 infection. Five patients
experienced at least one recurrence of CD associated diarrhea (CDAD) with a total of 12 relapsing episodes. Of
these, two patients had 5 and 6 relapses respectively.
We compared the 10 patients with 027 CDAD versus the 7 patients with non-027 CDAD. None of the 7 patients
with non-027 CDAD had a recent history of LTCF admission and no subsequent relapses were observed (p = 0.04).
Conclusions: Our study shows that CD 027 is emerging in healthcare facilities in Italy. Whilst nosocomial
acquisition accounted for the majority of such cases, 4 patients had history of a recent stay in a LTCF. We highlight
the substantial risks of this highly transmissible organism in such environments. Moreover, 50% of our patients with
CDAD from the 027 strain had high relapse rates which may serve to further establish this strain within the Italian
health and social care systems.
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Clostridium difficile (CD) is a major cause of antibiotic-
associated diarrhea (ADD) and whilst it is responsible
for 15-25% of all cases of ADD, there is a greater asso-
ciation when severe features of disease are accounted for
[1]. It predominantly affects elderly and frail hospital
and nursing home patients [2] causing a broad spectrum
of clinical symptoms ranging from mild diarrhea to se-
vere life-threatening colonic perforation and toxic mega-
colon [3].* Correspondence: nicola.petrosillo@inmi.it
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reproduction in any medium, provided the orOver the last two decades many countries in North
America and Europe have begun to register important
epidemiological changes regarding CD infections and
the related severity [4]. For example, Canada reported an
increase in Clostridium difficile associated disease
(CDAD) from 35.6 cases per 100,000 persons in 1991
to 156.3 per 100,000 in 2003 [5] and in the United
Kingdom (UK) a six fold increase in Clostridium difficile
infection (CDI) related mortality was observed from
1999 to 2006 [6].
This changing epidemiology in developed countries
coincided with the emergence of a hypervirulent strain
of CD characterized as toxinotype III, North American
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ribotype 027 [7,8]. These “epidemic” strains isolated in
North America and Europe appear to be genetically
similar [9] and in recent months, cases of CDI caused by
PCR ribotype 027 have been reported in Asia [10], pro-
viding further evidence of worldwide spread.
Associations between strain type and disease severity
have been hypothesised and it is documented that when
compared to other circulating strains, CD 027 is asso-
ciated with a more severe disease course and a higher
mortality rate [11,12]. A prospective study of CDIs con-
ducted in Europe, spanning 14 countries, reported that
patients infected with the 027 strain were three times
more likely to have severe disease compared to those
infected with non-027 strains [13].
In an effort to understand this strain specific virulence,
bacterial factors have been evaluated during outbreaks of
CDI caused by the virulent 027 strain. Increased produc-
tion of toxins A and B, fluoroquinolone resistance and
production of binary toxin have all been observed with
this epidemic strain [2]. Indeed, this ‘hypervirulent
strain’ produces up to 16 times more toxin A and 23
times more toxin B compared to non-027 circulating
strains (toxinotype 0) [14].
In North America, the 027 strain accounts for 63% of
health care-associated CDI [15]. Across Europe, 014/020
PCR ribotype is the commonest, with CD 027 account-
ing for 19 out of 389 (5%) of toxigenic isolates collected
across 34 countries [16]. Of interest, none of the 027
strains were identified in Italy which is consistent with
surveillance data from an earlier study; of the 50
fluoroquinolone-resistant CD clinical isolates analysed
from Italian hospitals from 1985 to 2008 were analysed,
none were identified as PCR ribotype 027 [17].
However, in 2010, CD 027 was identified in our coun-
try and the first documented case occurred in Northern
Italy [18]. A single hospital reported 8 cases of severe
CD (6% of the 130 tested CD isolates) caused by 027.
Since then, no further reports have been published. In
this article, we describe ten further cases of CD 027 in-
fection occurring in central Italy over the two year
period since this first documentation.Methods
The National Institute for Infectious Diseases in Italy,
“Lazzaro Spallanzani”, serves as a national reference
centre for several infectious diseases including nosoco-
mial infections.
During the last 6 years almost 1,500 stool samples
were submitted to our laboratory to be tested for CD
toxins by enzyme immunoassay (EIA), with a total of 48
CDAD episodes. EIA testing for toxin A and B detection
was performed by using the TechLab Tox A/B QuikChek (rapid antigen capture; TechLab). Glutamate de-
hydrogenase (GDH) test is not routinely performed.
In December 2010, we procured the Xpert C. difficile
PCR assay (Cepheid, Sunnyvale, CA). Surrounding local
hospitals have the capacity to perform CD toxin testing
by EIA but they refer to our centre to perform CD PCR
on stool samples of patients with severe diarrhea i.e. in
those who they have a clinical suspicion of the presence
of a hypervirulent strain as suggested by symptom
severity.
The Xpert multiplex real-time PCR assay detects toxin
B gene (tcdB), the binary toxin gene (cdt), and the tcdC
gene deletion at nucleotide 117 which is specific to the
epidemic strain NAP1/BI/027. The test differentiates be-
tween the epidemic NAP1/BI/027 CD strains and other
toxigenic CD strains with excellent correlation to PCR-
ribotyping for detection of 027 strains [19]. The self-
contained, single-use cartridge contains all the reagents
necessary for the detection of C. difficile gene targets.
Stool samples that were positive for tcdB, cdt and a sin-
gle nucleotide deletion at base 117 in tcdC were reported
as NAP1/BI/027. Samples that were positive only for
tcdB or for tcdB plus cdt were reported as NAP1/BI/027
negative, toxigenic C. difficile positive .
Clinical definitions described by the European Society
of Clinical Microbiology and Infectious Diseases (ESC-
MID) [20], by the Society for Healthcare Epidemiology
of America (SHEA) and the Infectious Diseases Society
of America (IDSA) [21] were used for CDAD.
CDAD was defined as diarrhea and a stool sample
positive for CD toxin A and/or B, as determined using a
laboratory assay. CDAD was defined as severe in
patients with leukocytosis i.e. white blood cells equal to
or in excess of 15,000 cells/μL and/or a serum creatinine
level greater than or equal to 1.5 times the premorbid
level. A complicated course of CDAD was defined as ad-
mission to an intensive care unit (ICU), surgical inter-
vention or death associated with CDAD.
Health care-associated CDAD was defined as the de-
velopment of CDAD more than 48 hours after admission
or within 4 weeks after discharge. Community associated
CDAD (CA-CDAD) was defined as a positive CD toxin
assay in a patient with diarrhea and no documented
prior overnight hospitalization or long term care facility
stay in the preceeding 3 months. CDAD cases that oc-
curred between 4 and 12 weeks after hospital discharge
were defined indeterminate. The specimen should have
been collected as an outpatient or within 48 hours of
hospital admission. Recurrence was defined as an epi-
sode of diarrhea that occurred ≤ 8 weeks after the onset
of a previous episode.
Clinical, epidemiological and laboratory data of
patients with CDAD caused by CD 027 were collected.
The study involved the analysis of existing clinical and
Table 1 Characteristics of patients with severe diarrhea




- Female 8/10 (80%)
Comorbidities
- Diabetes 3/10 (30%)
- Cardiovascular system disease 7/10 (70%)
- Respiratory system disease 2/10 (20%)
- HIV infection 0/10 (0%)
Inflammatory bowel disease 1/10 (10%)
Immunosuppressive treatment 3/10 (30%)
Acid-suppressant drugs 5/10 (50%)
Antibiotics in the prior 3 months 9/10 (90%)
Occult faecal blood 5/6 (83%)
Leukocytosis (≥ 11.000 WBCs) 5/9 (56%)
Hypoalbuminemia 5/6 (83%)
Hypogammaglobulinemia 4/5 (80%)
Previous LTCF stay 4/10 (40%)
Healthcare-associated CDAD 9/10 (90%)
Severe or complicated CDAD 6/10 (60%)
Recurrence of CDAD 5/10 (50%)
The total of patients was referred to those whose data were available.
CDAD: Clostridium difficile-associated disease; LTCF: long term care facility;
WBCs: white blood cells.
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included in the study database. Thus, according to local
and national regulations, this analysis was exempt from
formal approval by the Ethics Committee.
Statistical analysis was performed using the χ2 test or
the Fisher’s exact test when appropriate, and the results
were considered to be significant at p < 0.05.
Results
From December 2010 to April 2012, 24 faecal samples
from 19 patients with severe diarrhea and clinical suspi-
cion of a hypervirulent strain were submitted to our la-
boratory, from 7 hospitals.
Of these 19 patients, 17 had a positive PCR for CD
and of these, 10 were the epidemic 027 strain (59%). All
samples with a positive PCR for CD had a positive EIA
test for toxin A and B.
Among the CD 027 patients, 4 were admitted in surgi-
cal units, whereas in the non-027 group only 2 were ad-
mitted in surgical units at the time of the diagnosis; the
remaining patients, but one (the CA-CDAD case) were
admitted in medical units.
Among the 10 CD 027 positive patients, 8 were fe-
male. The median age was 77 years (range 29–89 years).
4/10 had a history of admission to a long term care faci-
lity in the 3 months prior to the diagnosis of CDAD and
overall, 9/10 were defined as health care-associated. The
majority of CD 027 patients (9/10) were exposed to anti-
microbials (including third generation cephalosporins
and quinolones) in the 3 months preceeding diagnosis of
CDI. Five out of 10 patients were taking proton pump
inhibitors (PPIs). Table 1 shows the characteristics of
these 10 patients, in whom the most prevalent co-
morbidity was cardiovascular system disease, possibly
reflecting the age distribution of these patients.
Among the 027 infected group, one patient had
chronic hepatitis C. Among the non-027 group there
were: 1 patient with pulmonary tuberculosis, 1 AIDS pa-
tient with tuberculous meningitis and urinary tract in-
fection, and 1 AIDS patient with extrapulmonary
tuberculosis (lymph nodes) and esophageal candidiasis.
No patients were diagnosed as having any bacterial,
protozoan or elmintic enteric infection.
Five out of 10, three of whom were taking PPIs,
experienced at least one recurrence of CDI with a total
of 12 relapsing episodes. Of these, two patients had 4
and 5 relapses respectively. Amongst the five patients
who experienced recurrence episodes, 4 were female.
The management of the 10 patients with C. difficile
027 infection was as follows: 2 patients were treated with
oral metronidazole alone; one patient was treated with
oral vancomycin alone; 7 patients were treated with
metronidazole and vancomycin in combination (# = 4)
or sequentially (# = 3). No patients died. Both patientstreated only with metronidazole had one recurrence
each. The other 10 recurrences occurred in the patients
treated with both vancomycin and metronidazole
The single community associated-CD patient was the
wife of a patient who had hospital acquired CD 027 in-
fection. She had no exposure to antimicrobials in the
previous 3 months and developed diarrhea 5 days after
her husband was discharged from hospital. All other
usual aetiologies of acute diarrhoea were excluded by
conventional cultures and parasitological examinations.
One patient had a concurrent diagnosis of ulcerative
colitis and represents the first report of a patient with
inflammatory bowel disease (IBD) with CD 027 detected
in this country. This was a female patient, with no his-
tory of previous long-term healthcare stay. At 29 years
of age, this was the youngest patient in our case series.
Serum albumin measurement was available for 6/10
patients and showed that 5/6 were hypoalbuminaemic at
the time of CDAD diagnosis, with a mean albumin level
of 2.5 g/dl (laboratory range 3.5-5 g/dl). IgG levels were
measured in 5 patients; 4 of them had low serum IgG
levels, i.e. 681, 612, 714 and 910 mg/dl (laboratory range
1200–1500 mg/dl).
Five patients fulfilled the criteria for severe CDAD. A
further patient was diagnosed as having complicated
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There were no patient deaths in our small cohort.
We compared the 10 patients with CDAD caused by
027 versus the 7 patients with CDAD by non-027 toxi-
genic strains. None of the 7 patients with severe diarrhea
from CD non-027 had a history of admission in a long
term care facility in the 3 months prior to the diagnosis
of CDAD (p = 0.08) and no subsequent relapses of
CDAD were observed (p = 0.04).
Discussion
Our study shows that CD 027 is emerging in healthcare
facilities in our region, causing a spectrum of disease se-
verity and relapsing episodes. According to our data,
50% of patients with CDAD from CD 027 experienced at
least one recurrence episode of CDAD. CDAD recurs
after treatment in 8-50% of cases [22] with recent
reports of an upsurge in recurrence rates in some coun-
tries, likely due to several interplaying factors [23].
Unlike in other parts of Europe, there is currently no
national CD surveillance program in Italy. The first cases
of CD 027 were reported in 2010 [18] and due to varia-
tions in application of clinical definitions, methodology
of detection and incomplete strain specific data, we do
not yet know the exact magnitude of the problem. It is
likely that the small number of cases described to date
represents only the ‘tip of the iceberg’ and we hypothe-
sise that the incidence of CD 027 in our hospitals is ri-
sing in real terms. This would be consistent with the
pattern of spread of this epidemic strain in other parts
of the world.
Long term care facilities such as nursing homes are
being increasingly recognised as important reservoirs of
pathogens including multidrug resistant bacteria and CD
027, within the community. Our study reported that
40% of patients had a previous stay in a long term care
facility and it is likely that the high spore load associated
with these settings is contributing to the persistence of
CD outside of the hospital environment.
In Italy, community onset diarrhea is rarely investi-
gated for CD. The patient with diarrhea secondary to
CD 027 in the community had a strong contact history
which prompted investigation. However, we must be
vigilant that, as these 10 patients with CDAD 027 were
not knowingly linked in time and place i.e. direct trans-
mission events are unlikely, the community may also act
as an important reservoir for CD 027 transmission [24].
The importance of CDI amongst patients with IBD is
increasingly being recognized and recent studies have
demonstrated increasing rates of infection, morbidity
and mortality, especially in patients with ulcerative col-
itis [25-27]. IBD guidelines now promote testing for CD
in IBD patients experiencing a relapse of symptoms [28].
In our case series, only one patient had a concurrentdiagnosis of ulcerative colitis and indeed had a super-
added CD infection.
Establishing an IgG response to CD has been shown
to protect against infection and prevent recurrence. Of
the 4 patients with a low serum gammaglobulin level, 2
had a high burden of recurrent disease with a total of 9
relapsing episodes and another had complicated CDAD
requiring ICU admission. This supports the role of
humoral immunity in protecting from recurrence epi-
sodes of CDAD [2].
It has been previously documented that male patients
mount an augmented serum antibody response to CDI
when compared to females. Furthermore, male patients
are documented to have less recurrent episodes which is
consistent with our findings that, of the five patients
who experienced recurrence episodes, 4 were female
[29,30]. Surveillance data that provides more informa-
tion about patient specific factors that may influence
outcome of CDAD, may allow us to tailor future ma-
nagement of this infection.
Despite a small case series, we have noted important
differences between our patients with CDAD from 027
versus CDAD from other toxigenic strains. Indeed, pre-
vious long term care facility admission and recurrent
episodes were more common in the CD 027 group. This
supports recent literature which highlights long term
care facilities as an important ecological niche for CD
027 [5,31,32]. In addition, our data agrees with reports
by Pepin et al. who document an increase in the likeli-
hood of recurrence from 20% to 47% after infection with
CD 027 [23]. Similarly, Goorhuis et al. found clear
trends in recurrence among patients with CDAD from
ribotype 027 as did a recent paper from Petrella et al.
[33,34].
Rapid PCR diagnostics can provide accurate, real-time
results regarding CD positivity and 027 strain presence.
Early knowledge of an epidemic strain within our health-
care facilities, may optimise clinical management of
CDAD and allow rapid enhancement of infection control
practices. Halting the success of this strain in becoming
the single predominant strain circulating in healthcare
institutions may require such an approach.
Whilst no single test is 100% sensitive and specific for
the detection of C. difficile, cell cytotoxin and cytotoxi-
genic culture reference tests are the current gold stan-
dards. A limitation of our study is that neither are
available in our laboratory for confirmation of the PCR
results and subsequent ribotyping was also not possible.
Our current practice is to only test stool from patients
with severe diarrhea for CD 027 by the Xpert real-time
PCR assay so there is the possibility that we may over-
estimate the true frequency of CD 027 infection among
patients with CDAD in our country. However, this re-
port represents an epidemiological alert since in a recent
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among Italian CDAD [16].
Conclusions
This data confirms the emergence of CD 027 in our
country and underlines the association of this strain with
the increased severity of CDAD and the higher rates of
recurrence episodes. Surveillance data are urgently
needed in order to better assess the diffusion of CD 027
in Italy and to establish risk factors associated with the
transmission of CD 027 in our healthcare facilities. With-
out this knowledge, we have a limited armamentarium
against the emerging threat of this fastidious pathogen.
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